Injectable platelet-rich fibrin (i-PRF) is a novel platelet concentrate that has been employed in dentistry with the objective of promoting tissue regeneration and healing. In contrast to platelet-rich plasma (PRP), i-PRF is more straightforward to handle, more cost-effective, and free from anticoagulants, which reduces biochemical alterations. The i-PRF procedure was developed in 2014 by adjusting the centrifugation forces. The resulting product remains in a liquid state for approximately 15 minutes, gradually transforming into a growth factor-rich clot that releases continuously over 10-14 days. It has demonstrated efficacy in a range of dental applications. In periodontology, i-PRF is an effective treatment for periodontitis, enhancing gingival thickness and reducing inflammation, plaque, and recession. Furthermore, it enhances the outcomes of periodontal regenerative surgery and lichen planus treatment. In oral surgery, i-PRF has been shown to facilitate bone regeneration, fistula resolution, and sinus augmentation. Orthodontic studies have indicated that i-PRF accelerates tooth movement and bone remodeling. However, osteomicroperforation remains more effective for some treatments. A limited number of endodontic studies have indicated that i-PRF may support revascularisation and periapical healing. In conclusion, i-PRF's regenerative capabilities, anti-inflammatory and antimicrobial properties offer significant potential in dentistry, and further exploration and application is therefore warranted.